Dark

Check out our Level2View

FPRX
Five Prime Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Apr 15, 2021

38.00USD+0.026%(+0.01)1,006,601

Pre-market

0.00USD-100.000%(-37.99)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Apr 16, 2021

08:27AM EDT Amgen Completes Acquisition Of Five Prime Therapeutics For $38/Shr Cash RTTNews

08:25AM EDT Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire

Mar 19, 2021

02:29PM EDT Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors Benzinga

Mar 11, 2021

06:55PM EST FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX Business Wire

Mar 10, 2021

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 9, 2021

05:05PM EST Five Prime Cancels Q4, FY 2020 Conference Call Benzinga

05:00PM EST Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call Business Wire

10:22AM EST Earnings Outlook for Five Prime Therapeutics Benzinga

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021 Benzinga

09:15AM EST Guggenheim Downgrades Five Prime Therapeutics to Neutral, Announces $38 Price Target Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 5, 2021

10:29AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021 Benzinga

06:04AM EST Jefferies Downgrades Five Prime Therapeutics to Hold, Announces $38 Price Target Benzinga

Mar 4, 2021

02:52PM EST Mid-Afternoon Market Update: Nasdaq Tumbles Over 200 Points; Five Prime Therapeutics Shares Spike Higher Benzinga

12:26PM EST Mid-Day Market Update: Dow Turns Positive; Schrdinger Benzinga

11:35AM EST Amgen Pays $1.9B For Five Prime Therapeutics Acquisition Benzinga

10:26AM EST Mid-Morning Market Update: Markets Open Lower; Kroger Posts Mixed Q4 Results Benzinga

08:42AM EST Amgen (AMGN) has agreed to acquire Five Prime Therapeutics (FPRX) for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. The acquisition includes Bemarituzumab, a phase 3 ready, first-in-class program for Gastric Cancer. RTTNews

08:36AM EST Five Prime Therapeutics Shares To Resume Trade At 9 a.m. EST Benzinga

08:32AM EST Amgen To Acquire Five Prime Therapeutics For $38/Shr Cash, Representing An Equity Value Of $1.9 Bln RTTNews

08:32AM EST Amgen To Acquire Five Prime Therapeutics For $1.9B Cash, $38/Share Benzinga

08:31AM EST Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash PR Newswire

Mar 2, 2021

04:05PM EST Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call Business Wire

Feb 26, 2021

05:00PM EST Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference Business Wire

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 22, 2021

06:00PM EST Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference Business Wire

Feb 16, 2021

10:31AM EST Five Prime Therapeutics 13G Filing From RTW Investments Shows New 5.73% Stake In Co. Benzinga

Feb 5, 2021

09:25AM EST Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day Business Wire

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

06:59AM EST Five Prime Therapeutics Presents Phase 2 FIGHT Trial Results Of FGFR2b RTTNews

06:58AM EST Five Prime Therapeutics Highlights Presentation Of Phase 2 FIGHT Trial Results At ASCO; Says All three Efficacy Endpoints (PFS, OS and ORR) Met Pre-Specified Statistical Significance Benzinga

06:56AM EST Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers Business Wire

Jan 9, 2021

01:02PM EST The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off Benzinga

Dec 9, 2020

05:03PM EST Five Prime To Present Phase 2 FIGHT Trial Results Of Bemarituzumab At American Society Of Clinical Oncology Annual Symposium Benzinga

05:00PM EST Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium Business Wire

Nov 17, 2020

05:00PM EST Five Prime Announces Closing of Upsized Public Offering of Common Stock Business Wire

Nov 16, 2020

01:06PM EST When To Follow Trend Benzinga

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 12, 2020

10:16PM EST Five Prime Therapeutics Announces Pricing Of Underwritten Public Offering Of 7.20 Mln Shares At $21.00/shr RTTNews

10:00PM EST Five Prime Announces Pricing of Upsized Public Offering of Common Stock Business Wire

12:25PM EST Mid-Day Market Update: Nasdaq Turns Lower; EuroDry Shares Jump After Q3 Results Benzinga

11:53AM EST Why Five Prime Therapeutics Stock Is Trading Higher Today Benzinga

10:19AM EST Mid-Morning Market Update: Markets Mixed; TransDigm Earnings Top Estimates Benzinga

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

05:47PM EST Five Prime Presented Its First Preclinical Data On Its Anti-CCR8 Antibody FPA157 Benzinga

05:45PM EST Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157 Business Wire

04:04PM EST Five Prime Announces Proposed Public Offering Of Common Stock RTTNews

04:01PM EST Five Prime Announces Proposed Public Offering of 5M Shares of Common Stock Benzinga

04:01PM EST Five Prime Announces Proposed Public Offering of Common Stock Business Wire

02:52PM EST Mid-Afternoon Market Update: Nasdaq Gains 1.6%; Five Prime Therapeutics Shares Jump Benzinga

01:28PM EST Yahoo Finance Trending Stocks For Wednesday, Nov. 11, 2020: FPRX, DDOG, FTEK, VXRT, RKT, PLUG, SRNE, REV, GNUS, SPCE, MYO, FUBO, MRNA, PSHG, IMRN, MAPT, LYFT, BRKS, PACB, APD, NKLA, QCOM, MOMO, OASPQ, LMND, COHR, PDD, EQ, MDGS Benzinga

12:50PM EST Mid-Day Market Update: Crude Oil Rises 2%; Aurora Cannabis Shares Plunge Benzinga

10:15AM EST Mid-Morning Market Update: Markets Mostly Higher; Air Products Reports Mixed Q4 Results Benzinga

09:56AM EST ROCE Insights For Five Prime Therapeutics Benzinga

09:53AM EST Benzinga's Top Upgrades, Downgrades For November 11, 2020 Benzinga

09:51AM EST Shares of Five Prime Therapeutics, Inc. (FPRX) surged over four-fold on Wednesday morning after its gastric-cancer treatment met all three of its efficacy endpoints in a mid-stage trial. RTTNews

08:13AM EST SVB Leerink Reiterates Outperform on Five Prime Therapeutics, Raises Price Target to $33 Benzinga

08:06AM EST Five Prime Therapeutics Block Trade of 500,000 Shares @ $22.00 Above Ask of $21.61 Benzinga

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

06:11AM EST JP Morgan Upgrades Five Prime Therapeutics to Neutral, Announces $14 Price Target Benzinga

06:10AM EST Wells Fargo Upgrades Five Prime Therapeutics to Overweight, Announces $34 Price Target Benzinga

Nov 10, 2020

04:52PM EST Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free And Overall Survival Benefit Compared To Placebo Plus Chemotherapy In Front-Line Advanced Gastric, Gastroesophageal Junction Cancer Benzinga

04:12PM EST Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer Business Wire

Nov 4, 2020

01:38PM EST Five Prime Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results. Benzinga

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

04:09AM EST SVB Leerink Maintains Outperform on Five Prime Therapeutics, Lowers Price Target to $9 Benzinga

Nov 3, 2020

04:21PM EST Recap: Five Prime Therapeutics Q3 Earnings Benzinga

04:06PM EST Five Prime Therapeutics Q3 EPS $(0.74) Misses $(0.60) Estimate Benzinga

04:05PM EST Five Prime Therapeutics Reports Third Quarter 2020 Results Business Wire

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

04:07AM EST Earnings Scheduled For November 3, 2020 Benzinga

Nov 2, 2020

06:30PM EST Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting Business Wire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 27, 2020

10:29PM EDT Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call Business Wire

Oct 13, 2020

05:14AM EDT Five Prime Therapeutics 10%+ Owner Mark Lamper Reported Purchase of 345,241 Shares @ Avg Price of $5.04/Share in Form 4 Filing on Monday Benzinga

Sep 22, 2020

12:48PM EDT Five Prime Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a price target of $11 per share. Benzinga

09:36AM EDT Benzinga's Top Upgrades, Downgrades For September 22, 2020 Benzinga

07:32AM EDT Guggenheim Upgrades Five Prime Therapeutics to Buy, Announces $11 Price Target Benzinga

Sep 9, 2020

06:30PM EDT Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference Business Wire

Aug 6, 2020

04:58PM EDT Five Prime Therapeutics Q2 EPS $(0.48) Beats $(0.69) Estimate, Sales $3.42M Miss $4.58M Estimate Benzinga

04:06PM EDT Five Prime Therapeutics Reports Second Quarter 2020 Results Business Wire

Jul 29, 2020

07:00PM EDT Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire

06:30PM EDT Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call Business Wire

Jul 20, 2020

05:11AM EDT 80 Biggest Movers From Friday Benzinga

Share